Status and phase
Conditions
Treatments
About
This study adopts multicenter/randomized trial design. It plans to enroll patients with HR- positive, HER2- negative advanced breast cancer who are resistant to (neo)adjuvant endocrine therapy. Dose-escalation and dose-expansion studies will be carried out to evaluate the safety, tolerability, and preliminary efficacy of sirolimus (albumin-bound) in combination with palbociclib and fulvestrant in this patient population.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
382 participants in 1 patient group
Loading...
Central trial contact
Clinical Trials Information Group officer
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal